PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.79%
Revenue growth of 0.79% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
66.19%
Gross profit growth of 66.19% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
131.77%
EBIT growth of 131.77% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
131.77%
Operating income growth of 131.77% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
94.53%
Net income growth of 94.53% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
94.63%
EPS growth of 94.63% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
94.63%
Diluted EPS growth of 94.63% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
0.77%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.77%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-1372.80%
Negative OCF growth while Healthcare median is -19.97%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-213.23%
Negative FCF growth while Healthcare median is -17.44%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
2699.78%
5Y CAGR of 2699.78% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
995.84%
3Y CAGR of 995.84% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
-10471.05%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-1899.91%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-745.55%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-322.72%
Negative 10Y net income/share CAGR vs. Healthcare median of 15.18%. Seth Klarman might see a fundamental problem if peers maintain growth.
-96.58%
Negative 5Y CAGR while Healthcare median is 19.29%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-115.70%
Negative 3Y CAGR while Healthcare median is 9.02%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
5649.27%
Equity/share CAGR exceeding 1.5x Healthcare median of 20.78% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
2476.44%
5Y equity/share CAGR > 1.5x Healthcare median of 19.83%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
188.63%
3Y equity/share CAGR > 1.5x Healthcare median of 12.14%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.57%
AR growth of 53.57% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
37.86%
Inventory growth of 37.86% while Healthcare median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
5.69%
Asset growth of 5.69% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
5.89%
BV/share growth of 5.89% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
8.09%
Slightly rising debt while Healthcare median is deleveraging. Peter Lynch wonders if the firm lags behind peers in risk control or invests in more expansions.
-72.57%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
8.97%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.